RVL Pharmaceuticals plc
NASDAQ:RVLP
| Market Cap (Intraday) | 10.50M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $0.11 |
| 50-Day MA | $0.27 |
| 200-Day MA | $0.85 |
RVL Pharmaceuticals plc Stock, NASDAQ:RVLP
400 Crossing Boulevard, Bridgewater, New Jersey 08807
United States of America
Phone: +1.908.809.1300
Number of Employees: 125
Description
RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.